TransMedics Group, Inc. (NASDAQ:TMDX) Stock Position Lifted by Barclays PLC

Barclays PLC boosted its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDXFree Report) by 20.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 182,609 shares of the company’s stock after purchasing an additional 31,092 shares during the quarter. Barclays PLC owned 0.56% of TransMedics Group worth $9,999,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Huntington National Bank bought a new position in shares of TransMedics Group during the 2nd quarter worth about $30,000. Global Retirement Partners LLC bought a new position in shares of TransMedics Group during the 3rd quarter worth about $38,000. Ancora Advisors LLC acquired a new stake in shares of TransMedics Group during the 1st quarter worth about $38,000. First Horizon Advisors Inc. increased its position in shares of TransMedics Group by 45.1% during the 1st quarter. First Horizon Advisors Inc. now owns 544 shares of the company’s stock worth $41,000 after purchasing an additional 169 shares in the last quarter. Finally, Belpointe Asset Management LLC increased its position in shares of TransMedics Group by 51.6% during the 1st quarter. Belpointe Asset Management LLC now owns 558 shares of the company’s stock worth $42,000 after purchasing an additional 190 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at TransMedics Group

In other news, Director James R. Tobin sold 10,000 shares of TransMedics Group stock in a transaction that occurred on Tuesday, November 28th. The shares were sold at an average price of $70.14, for a total transaction of $701,400.00. Following the completion of the sale, the director now owns 233,591 shares in the company, valued at approximately $16,384,072.74. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, VP Miriam Provost sold 4,122 shares of TransMedics Group stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $75.10, for a total transaction of $309,562.20. Following the transaction, the vice president now owns 23,820 shares of the company’s stock, valued at approximately $1,788,882. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director James R. Tobin sold 10,000 shares of TransMedics Group stock in a transaction that occurred on Tuesday, November 28th. The stock was sold at an average price of $70.14, for a total transaction of $701,400.00. Following the transaction, the director now directly owns 233,591 shares in the company, valued at approximately $16,384,072.74. The disclosure for this sale can be found here. Insiders sold a total of 56,452 shares of company stock worth $4,462,772 in the last quarter. 6.70% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

TMDX has been the subject of a number of recent analyst reports. Morgan Stanley increased their target price on shares of TransMedics Group from $54.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Monday, December 4th. JPMorgan Chase & Co. increased their target price on shares of TransMedics Group from $67.00 to $70.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 7th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, TransMedics Group has a consensus rating of “Moderate Buy” and an average price target of $83.33.

View Our Latest Research Report on TransMedics Group

TransMedics Group Stock Performance

TMDX opened at $86.68 on Wednesday. The company has a debt-to-equity ratio of 4.00, a quick ratio of 10.13 and a current ratio of 10.93. TransMedics Group, Inc. has a 1-year low of $36.42 and a 1-year high of $99.63. The firm has a 50-day moving average price of $79.91 and a two-hundred day moving average price of $67.27.

TransMedics Group (NASDAQ:TMDXGet Free Report) last issued its quarterly earnings results on Monday, November 6th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.06. TransMedics Group had a negative net margin of 18.65% and a negative return on equity of 8.77%. The company had revenue of $66.43 million during the quarter, compared to analysts’ expectations of $48.05 million. As a group, analysts expect that TransMedics Group, Inc. will post -0.33 earnings per share for the current year.

About TransMedics Group

(Free Report)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Featured Articles

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDXFree Report).

Institutional Ownership by Quarter for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.